A faded penny stock player folds its cards and hands over the keys in reverse merger

After bumping along the bottom of the charts as a penny-stock player for most of the past 2 years, the oncology biotech Advaxis is handing over its limited pipeline and cash on hand to Biosight as the hematology startup reverses onto Nasdaq.

Advaxis shares closed Friday at 47 cents, right...

Click to view original post